US 12,290,498 B2
Methods of treatment of cholestatic diseases
Remy Hanf, Lille (FR)
Assigned to Genfit, Loos (FR)
Filed by Genfit, Loos (FR)
Filed on Nov. 9, 2023, as Appl. No. 18/506,013.
Application 18/506,013 is a continuation of application No. 17/533,767, filed on Nov. 23, 2021, granted, now 12,053,445.
Application 17/533,767 is a continuation of application No. 16/894,110, filed on Jun. 5, 2020, granted, now 11,331,292, issued on May 17, 2022.
Application 17/533,767 is a continuation of application No. 16/090,415, granted, now 11,185,519, issued on Nov. 30, 2021, previously published as PCT/EP2017/057634, filed on Mar. 30, 2017.
Claims priority of application No. 16305381 (EP), filed on Mar. 31, 2016.
Prior Publication US 2024/0082186 A1, Mar. 14, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/192 (2006.01); A61K 45/06 (2006.01); A61P 37/06 (2006.01)
CPC A61K 31/192 (2013.01) [A61K 45/06 (2013.01); A61P 37/06 (2018.01)] 14 Claims
 
1. A method for reducing the need for liver transplantation in a subject having primary biliary cholangitis (PBC), the method comprising orally administering to the subject a composition comprising elafibranor or a pharmaceutically acceptable salt of elafibranor at a dose between 70 mg and 130 mg per administration.